Research Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
J Diet Suppl. 2024;21(3):294-312. doi: 10.1080/19390211.2023.2263788. Epub 2023 Oct 11.
Nonalcoholic fatty liver disease (NAFLD) is a prominent etiological factor for liver cirrhosis worldwide. It is frequently associated with obesity, diabetes, dyslipidemia, and hypertension. The objective of this study is to assess the efficacy and safety of ginger ( Roscoe) supplementation in patients with type 2 diabetes mellitus (T2DM) who have NAFLD. In a two-arm, double-blind, placebo-controlled clinical trial, seventy-six patients diagnosed with both T2DM and NAFLD were randomly assigned to receive either ginger powder capsules (1000 mg, twice daily) or placebo capsules (administered in the same manner) for a period of three months. Anthropometric measurements, blood pressure readings, biochemical profiles, and imaging parameters were assessed before and after the intervention. Safety measures were also evaluated. In both the ginger and placebo groups, there was a significant reduction in mean body mass index (BMI), waist and hip circumferences, as well as liver transaminase levels. Moreover, significant improvements in mean systolic and diastolic blood pressures were observed in the ginger group ( = 0.02 and < 0.0001, respectively). Within the ginger group, there was a decrease in serum insulin levels and insulin resistance (HOMA-IR) ( = 0.002 and 0.004, respectively). Furthermore, the ginger group exhibited an improvement in serum HDL-cholesterol level ( = 0.01). However, there were no significant changes in the assessed inflammatory markers or the indices obtained from fibroscan imaging, including steatosis percent and controlled attenuation parameter. This study demonstrates that ginger supplementation can significantly improve mean systolic and diastolic blood pressures. However, it does not have a significant impact on inflammatory markers or fibroscan imaging indices. Nonetheless, the three-month use of ginger improves serum insulin level, insulin resistance (HOMA-IR), and HDL-cholesterol level compared to baseline values. Further investigations with longer durations and larger sample sizes are recommended.
非酒精性脂肪性肝病（NAFLD）是全球肝硬化的一个主要病因。它常与肥胖、糖尿病、血脂异常和高血压有关。本研究旨在评估生姜（Roscoe）补充剂对患有非酒精性脂肪性肝病（NAFLD）的 2 型糖尿病（T2DM）患者的疗效和安全性。在一项双盲、安慰剂对照的临床试验中，76 例同时诊断为 T2DM 和 NAFLD 的患者被随机分为两组，分别接受生姜粉胶囊（1000mg，每日两次）或安慰剂胶囊（以相同方式给药）治疗，疗程为 3 个月。在干预前后评估了人体测量学指标、血压读数、生化谱和影像学参数。还评估了安全性措施。在生姜组和安慰剂组中，平均体重指数（BMI）、腰围和臀围以及肝转氨酶水平均显著降低。此外，生姜组的平均收缩压和舒张压均显著改善（ = 0.02 和 < 0.0001）。在生姜组中，血清胰岛素水平和胰岛素抵抗（HOMA-IR）降低（ = 0.002 和 0.004）。此外，生姜组的血清高密度脂蛋白胆固醇水平升高（ = 0.01）。然而，评估的炎症标志物或 fibroscan 成像指标（包括脂肪变性百分比和受控衰减参数）没有显著变化。本研究表明，生姜补充剂可显著改善平均收缩压和舒张压。然而，它对炎症标志物或 fibroscan 成像指标没有显著影响。尽管如此，与基线相比，生姜的三个月使用可改善血清胰岛素水平、胰岛素抵抗（HOMA-IR）和高密度脂蛋白胆固醇水平。建议进行持续时间更长、样本量更大的进一步研究。
